From enrolled patients we collected data including CFTR mutation, pancreatic insufficiency status (defined as fecal elastase value < 200 μg/g stool), anthropometric measurement (body weight, height and BMI z-score with the relative percentile), BIA PhA value (φ) performed by HUMAN-iM TOUCH, FEV1% as marker of lung function, liver disorders and glucose tolerance abnormalities. This evidence concerns the gene CFTR and exocrine pancreatic insufficiency.